Published in Am J Pathol on April 01, 2001
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol (2003) 1.52
Modulation of the tumor suppressor protein alpha-catenin by ischemic microenvironment. Am J Pathol (2009) 1.35
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci U S A (2003) 1.32
Abundant expression of Dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation. Biochem J (2002) 1.29
A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis (2005) 1.20
Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.08
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia (2011) 1.04
Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J (2003) 1.04
Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. Am J Pathol (2005) 0.97
Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res (2011) 0.92
High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer (2007) 0.89
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer (2010) 0.87
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. Br J Cancer (2013) 0.85
Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol (2010) 0.82
Relationship of hypoxia-inducible factor 1alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol (2006) 0.82
Hypoxia promotes tumor cell motility via RhoA and ROCK1 signaling pathways. Proc Natl Acad Sci U S A (2014) 0.81
Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma. Mol Ther (2010) 0.80
Krüppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells. Cancer Sci (2014) 0.78
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer (2014) 0.77
Lack of efficacy of combined antiangiogenic therapies in xenografted human melanoma. J Oncol (2011) 0.75
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. Cell Death Discov (2017) 0.75
MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo. J Cancer Res Clin Oncol (2017) 0.75
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer (1955) 10.49
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (1996) 10.14
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 6.86
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
Tumor heterogeneity. Cancer Res (1984) 6.17
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev (2000) 5.16
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med (1992) 4.76
Biological diversity in metastatic neoplasms: origins and implications. Science (1982) 3.95
Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat (1995) 3.88
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol (1994) 3.30
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol (1999) 3.15
Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics (1999) 2.12
Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol (2000) 2.10
Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev (1983) 1.96
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays (1991) 1.93
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.93
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer (1996) 1.84
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs (1995) 1.58
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer (1985) 1.57
Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res (1978) 1.48
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer (1985) 1.47
Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res (1996) 1.38
Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res (2000) 1.34
On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis (1982) 1.25
Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci (2000) 1.07
Intraneoplastic diversity. Biochim Biophys Acta (1982) 1.06
Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Rev (1996) 0.98
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis (2001) 12.85
Promotion of trophoblast stem cell proliferation by FGF4. Science (1998) 8.02
Z/AP, a double reporter for cre-mediated recombination. Dev Biol (1999) 6.88
In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med (2001) 5.54
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Generating green fluorescent mice by germline transmission of green fluorescent ES cells. Mech Dev (1998) 5.21
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Molecular mechanisms of blood vessel growth. Cardiovasc Res (2001) 3.94
Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res (1993) 3.59
Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development (2000) 3.44
Essential role of Mash-2 in extraembryonic development. Nature (1994) 3.36
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res (1995) 3.11
Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol (2001) 2.94
Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 2.86
Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med (1999) 2.81
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol (1998) 2.81
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res (2001) 2.78
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Long-term reconstitution of the mouse hematopoietic system by embryonic stem cell-derived fetal liver. Proc Natl Acad Sci U S A (1991) 2.66
Imprinted X inactivation maintained by a mouse Polycomb group gene. Nat Genet (2001) 2.63
Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol (1999) 2.59
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Genome manipulation in embryonic stem cells. Philos Trans R Soc Lond B Biol Sci (1993) 2.50
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost (2003) 2.49
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med (2001) 2.46
Genomic imprinting of Mash2, a mouse gene required for trophoblast development. Nat Genet (1995) 2.46
The orderly allocation of mesodermal cells to the extraembryonic structures and the anteroposterior axis during gastrulation of the mouse embryo. Development (1999) 2.45
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A (2001) 2.42
Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of Hnf-4(-/-) embryos. Development (1997) 2.41
A survey of the genomic distribution of alpha satellite DNA on all the human chromosomes, and derivation of a new consensus sequence. Nucleic Acids Res (1991) 2.39
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Enhanced immune responsiveness to a thymus-independent antigen early after adult thymectomy: evidence for short-lived inhibitory thymus-derived cells. Eur J Immunol (1972) 2.34
Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev (2000) 2.32
Non-injection methods for the production of embryonic stem cell-embryo chimaeras. Nature (1993) 2.27
Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst (1994) 2.25
Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest (1998) 2.19
Non-invasive sexing of preimplantation stage mammalian embryos. Nat Genet (1998) 2.16
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev (2001) 2.16
Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett (2001) 2.15
VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med (2000) 2.13
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. Cell (1974) 2.12
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3. Mol Cell Biol (2000) 2.11
Developmental abnormalities of glycosylphosphatidylinositol-anchor-deficient embryos revealed by Cre/loxP system. Lab Invest (1999) 2.06
Targeted insertion of Cre recombinase into the TNAP gene: excision in primordial germ cells. Genesis (2000) 2.05
The preparation and characterization of synaptic vesicles of high purity. Brain Res (1976) 2.00
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation (1999) 1.97
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.93
A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development (2001) 1.92
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg (1999) 1.85
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer (1996) 1.84
The organizer of the mouse gastrula is composed of a dynamic population of progenitor cells for the axial mesoderm. Development (2001) 1.83
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost (2008) 1.81
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood (1998) 1.81
Variable effects of anti-lymphocyte serum on humoral antibody formation: role of thymus dependency of antigen. J Immunol (1971) 1.80
An X-linked GFP transgene reveals unexpected paternal X-chromosome activity in trophoblastic giant cells of the mouse placenta. Genesis (2001) 1.73
Mash2 acts cell autonomously in mouse spongiotrophoblast development. Dev Biol (1997) 1.71
Genome engineering: the new mouse genetics. Nat Med (1995) 1.69
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1996) 1.66
TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol (1992) 1.66
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med (1996) 1.66
A cancer therapy resistant to resistance. Nature (1997) 1.65
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63
Hypothalamic hormones and cancer. Front Neuroendocrinol (2001) 1.61
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs (1995) 1.58
A needle-puncture that helped to change the world of surgery. Homage to János Veres. Surg Endosc (2000) 1.56
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A (1996) 1.54
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Generation and characterization of urokinase receptor-deficient mice. J Clin Invest (1996) 1.54
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature (1997) 1.50
Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab (2000) 1.49
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol (1998) 1.48
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer (1997) 1.48
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47
Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res (1997) 1.45
The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand (1981) 1.43
A mouse model for Zellweger syndrome. Nat Genet (1997) 1.43
Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res (2000) 1.42
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer (2008) 1.41
Modeling the Pauli potential in the pair density functional theory. J Chem Phys (2008) 1.39
Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev (1995) 1.39
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med (1997) 1.38
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res (1988) 1.36
Assessment of mitotic thymus-derived lymphocytes by their sensitivity to the cytotoxic effects of anti-theta serum. Cell Immunol (1974) 1.35
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol (2000) 1.33